Zydus Lifesciences is waiting for the National Technical Advisory Group on Immunization’s (NTAGI) clearance for vaccines for 12-18-year-olds, Sharvil Patel, managing director, told CNBC-TV18.
Recommended Articles
View All
Prakash Javadekar — Challenging task in hand as Kerala in-charge of BJP
Jan 30, 2023 IST8 Min(s) Read
New Locker Rules — Here's why the RBI has gone overboard
Jan 28, 2023 IST5 Min(s) Read
Meet Padma Shri Awardee Guru K Kalyanasundaram Pillai, the man who is keeping an ancient tradition alive
Jan 27, 2023 IST3 Min(s) Read
This is how the new draft IT rules propose to make online gaming safe
Jan 27, 2023 IST4 Min(s) Read
In an interview to CNBC-TV18, he said, “Between the age group of 12 and 18, for which we have already completed our trial and submitted it and waiting for, we already have a Drugs Controller General of India (DCGI) approval but waiting for NTAGI clearance to a booster dose strategy that has been worked out where we have to change vaccines from the earlier vaccination to the next vaccine to potentially then the younger age group of 5-12 and also the export market.”
Talking about the DNA platform, Patel said, “The DNA platform vaccine is a new platform that has been created by the company for COVID. This vaccine platform has the potential to be developed for other viruses as well and we will continue to work on that.”
Also Read: Zydus focusing on top 30 molecules; expects double-digit growth for India, says MD Sharvil Patel
However, said Patel, Zydus is not at a scale of producing a large number of COVID-19 vaccine doses, but the peak production estimate is 1 crore doses per month.
For more details, watch the accompanying video